Mayo Clinic Laboratory and pathology research roundup: November 8

By Samantha Rossi • November 8, 2022

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Evaluating the significance of pancreatobiliary fluorescence in situ hybridization polysomy on prognosis in de novo cholangiocarcinoma

We recently developed a fluorescence in situ hybridization probe set for evaluating suspicious biliary and pancreatic duct strictures (PB-FISH). We aimed to determine whether PB-FISH results in biliary brush cytology specimens are associated with outcomes of patients with cholangiocarcinoma (CCA). We performed a retrospective study of patients with CCA tested by PB-FISH from January 2015 to August 2018. Characteristics of 264 eligible patients (median age 60.4; range 18-92) were comparable for patients with PB-FISH polysomy vs nonpolysomy vs disomy. The median OS was similar between disomy, nonpolysomy, and polysomy in the overall population (22.7 vs 22.7 vs 20.3 months, respectively).

Read more.

Published to PubMed This Week

• Response by Borlaug and Shah regarding article, "Latent Pulmonary Vascular Disease and Therapeutic Atrial Shunt"
  Circulation, 146
• An opioid hiding in plain sight: loperamide-induced false-positive fentanyl and buprenorphine immunoassay results
  The journal of applied laboratory medicine, 7
• Author correction: exosome biopotentiated hydrogel restores damaged skeletal muscle in a porcine model of stress urinary incontinence
  NPJ Regenerative medicine, 7
• Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [alliance]
  Annals of oncology : official journal of the European Society for Medical Oncology, 33
• Cancer and vascular comorbidity effects on dementia risk and neuropathology in the oldest-old
  Journal of Alzheimer's disease : JAD, 90
• Preliminary reproducibility evaluation of a phage susceptibility testing method using a collection of escherichia coli and staphylococcus aureus phages
  The journal of applied laboratory medicine, 7
• Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?
  Leukemia, 36
• Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
  Frontiers in oncology
• Perioperative management of antiplatelet therapy: a systematic review and meta-analysis
  Mayo Clinic proceedings. Innovations, quality & outcomes, 6
• Flurofamide prevention and treatment of ureaplasma-induced hyperammonemia
  Microbiology spectrum, 10
• Molecular and immunophenotypic correlates of metastatic epithelioid angiomyolipoma include alterations of TP53, RB1, and ATRX
  Archives of pathology & laboratory medicine
• Malignant melanotic nerve sheath tumor
  AJNR. American journal of neuroradiology

Samantha Rossi

Samantha Rossi is a Digital Marketing Manager at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.